- mail us help@24marketresearch.com
- Int'l 1(332) 2424 294 (Int'l)
TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Pharmacogenomics (PGx) is a branch of precision medicine that studies how an individual’s genetic makeup affects their response to drugs. It combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to tailor drug treatments for individual patients, improving efficacy and reducing adverse effects. By analyzing genetic variations, pharmacogenomics helps in developing personalized treatment plans, minimizing trial-and-error prescriptions, and optimizing drug dosages.
The global Pharmacogenomics (PGx) market is projected to grow from US$ 8,569.5 million in 2024 to US$ 14,590 million by 2030, reflecting a CAGR of 9.3% during the forecast period.
The rising adoption of precision medicine, technological advancements in genomic research, and the increasing prevalence of chronic diseases are driving market expansion. In 2023, North America accounted for the largest market share due to well-established healthcare infrastructure and robust investment in genomics research.
Drivers:
Rising Demand for Personalized Medicine – The shift towards individualized treatment plans is boosting the adoption of PGx.
Technological Advancements – The development of next-generation sequencing (NGS) and CRISPR-based gene editing enhances PGx applications.
Increasing Prevalence of Chronic Diseases – Cardiovascular diseases, cancer, and neurological disorders drive the need for effective drug response assessments.
Growing Government and Private Funding – Investments in genomic research propel market growth.
Expanding Applications Beyond Oncology – PGx is now widely used in cardiology, neurology, infectious diseases, and psychiatric disorders.
Restraints:
High Cost of PGx Testing – Expensive genetic testing limits accessibility.
Regulatory and Ethical Concerns – Privacy concerns and stringent regulations hinder market adoption.
Lack of Standardization – Variability in testing methods impacts consistency.
Limited Awareness and Adoption in Developing Regions – Emerging markets face challenges in PGx integration.
Opportunities:
Integration of AI and Big Data in PGx Research – AI-driven analytics can accelerate drug response predictions.
Expansion in Emerging Markets – Asia-Pacific and Latin America offer untapped growth potential.
Strategic Collaborations Between Pharma and Biotech Firms – Partnerships enhance research capabilities and commercial success.
Challenges:
North America
Largest market share due to robust R&D investment and early adoption of PGx.
Presence of leading pharmaceutical and biotech companies.
Favorable government policies supporting genomics research.
Europe
Strong regulatory framework promoting precision medicine.
Increasing adoption of PGx in oncology and neurology.
Rising collaborations between academic institutions and industry players.
Asia-Pacific
Fastest-growing region due to government initiatives in genomic research.
Expanding healthcare infrastructure and increasing awareness of PGx.
Growing number of pharmaceutical companies investing in personalized medicine.
South America
Slow but steady growth due to improving healthcare policies.
Increased investment in genetic research and diagnostics.
Middle East & Africa
Emerging market with potential for growth in precision medicine.
Limited adoption due to high testing costs and lack of trained professionals.
Key players in the Pharmacogenomics market include:
These companies focus on strategic partnerships, acquisitions, and product innovations to maintain market dominance. R&D investments in sequencing technologies and personalized medicine continue to drive competition.
Transgenomic, Inc.
What is the current market size of the Pharmacogenomics (PGx) market?
Which are the key companies operating in the Pharmacogenomics (PGx) market?
What are the key growth drivers in the Pharmacogenomics (PGx) market?
Which regions dominate the Pharmacogenomics (PGx) market?
What are the emerging trends in the Pharmacogenomics (PGx) market?
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Pharmacogenomics (PGx) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.